Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays

키워드

참고문헌 (91)

1. Merker JD, "Circulating tumor DNA analysis in patients with cancer : American Society of Clinical Oncology and College of American Pathologists joint review", J Clin Oncol, 36, pp.1631~1641 (2018)
2. Cho SM, "Cost-effectiveness analysis of three diagnostic strategies for the detection of EGFR mutation in advanced non-small cell lung cancer", Ann Lab Med, 43, pp.605~613 (2023)
3. Song HH, "Optimization of a protocol for isolating cell-free DNA from cerebrospinal fluid", Ann Lab Med (2023)[DOI]
4. Ignatiadis M, "Circulating tumor cells and circulating tumor DNA : challenges and opportunities on the path to clinical utility", Clin Cancer Res, 21, pp.4786~4800 (2015)
5. Mouliere F, "Circulating tumor-derived DNA is shorter than somatic DNA in plasma", Proc Natl Acad Sci U S A, 112, pp.3178~3179 (2015)
6. Kim SY, "Manual for guideline adaptation ver 2.0" (2011), National Evidence-based Healthcare Collaborating Agency
7. Chakravarty D, "OncoKB : a precision oncology knowledge base", JCO Precis Oncol, 2017, pp.PO.17.00011~ (2017)
8. Baker A, "A review of grading systems for evidence-based guidelines produced by medical specialties", Clin Med(Lond), 10, pp.358~363 (2010)
9. The Korean Society of Radiology, "2020 Clinical imaging guidelines for justification of diagnostic imaging study by types of patients", Korean Medical Guideline, ~ (2020)
10. Pascual J, "ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer : a report from the ESMO Precision Medicine Working Group", Ann Oncol, 33, pp.750~768 (2022)
11. Moding EJ, "Detecting liquid remnants of solid tumors : circulating tumor DNA minimal residual disease", Cancer Discov, 11, pp.2968~2986 (2021)
12. Henriksen TV, "The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA", Mol Oncol, 14, pp.1670~1679 (2020)
13. Kamat AA, "Circulating cell-free DNA : a novel biomarker for response to therapy in ovarian carcinoma", Cancer Biol Ther, 5, pp.1369~1374 (2006)
14. Jung M, "Changes in concentration of DNA in serum and plasma during storage of blood samples", Clin Chem, 49, pp.1028~1029 (2003)
15. van Ginkel JH, "Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics", Cancer Med, 6, pp.2297~2307 (2017)
16. Parpart-Li S, "The effect of preservative and temperature on the analysis of circulating tumor DNA", Clin Cancer Res, 23, pp.2471~2477 (2017)
17. Barra GB, "EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples", Clin Biochem, 48, pp.976~981 (2015)
18. Kloten V, "Liquid biopsy in colon cancer : comparison of different circulating DNA extraction systems following absolute quantification of KRAS mutations using Intplex allele-specific PCR", Oncotarget, 8, pp.86253~86263 (2017)
19. Morgan SR, "Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples", Clin Med Insights Pathol, 5, pp.15~22 (2012)
20. Meddeb R, "Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA", Clin Chem, 65, pp.623~633 (2019)
21. El Messaoudi S, "Circulating cell free DNA : preanalytical considerations", Clin Chim Acta, 424, pp.222~230 (2013)
22. Shin S, "Clinical practice guidelines for pre-analytical procedures of plasma epidermal growth factor receptor variant testing", Ann Lab Med, 42, pp.141~149 (2022)
23. Parikh AR, "Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer", Clin Cancer Res, 27, pp.5586~5594 (2021)
24. Medina Diaz I, "Performance of Streck cfDNA blood collection tubes for liquid biopsy testing", PLoS One, 11, pp.e0166354~ (2016)
25. Wang Q, "Real-time PCR evaluation of cell-free DNA subjected to various storage and shipping conditions", Genet Mol Res, 14, pp.12797~12804 (2015)
26. Chiu RW, "Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma", Clin Chem, 47, pp.1607~1613 (2001)
27. Meddeb R, "Quantifying circulating cell-free DNA in humans", Sci Rep, 9, pp.5220~ (2019)
28. Chan KC, "Effects of preanalytical factors on the molecular size of cell-free DNA in blood", Clin Chem, 51, pp.781~784 (2005)
29. Sozzi G, "Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays", J Natl Cancer Inst, 97, pp.1848~1850 (2005)
30. Pérez-Barrios C, "Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients : impact on biomarker testing", Transl Lung Cancer Res, 5, pp.665~672 (2016)
31. Sorber L, "A comparison of cell-free DNA isolation kits : isolation and quantification of cell-free DNA in plasma", J Mol Diagn, 19, pp.162~168 (2017)
32. Bronkhorst AJ, "Comparison of methods for the isolation of cell-free DNA from cell culture supernatant", Tumour Biol, 42, pp.1010428320916314~ (2020)
33. Jain M, "Direct comparison of QIAamp DSP Virus Kit and QIAamp Circulating Nucleic Acid Kit regarding cell-free fetal DNA isolation from maternal peripheral blood", Mol Cell Probes, 43, pp.13~19 (2019)
34. Diefenbach RJ, "Evaluation of commercial kits for purification of circulating free DNA", Cancer Genet, 228-9, pp.21~27 (2018)
35. Trigg RM, "Factors that influence quality and yield of circulating-free DNA : a systematic review of the methodology literature", Heliyon, 4, pp.e00699~ (2018)
36. Ponti G, "The value of fluorimetry(Qubit)and spectrophotometry(NanoDrop)in the quantification of cell-free DNA(cfDNA)in malignant melanoma and prostate cancer patients", Clin Chim Acta, 479, pp.14~19 (2018)
37. ICGC, "TCGA Pan-Cancer of Whole Genomes Consortium", Pan-cancer analysis of whole genomes, 2020, pp.578, 82~93
38. Tomczak K, "The Cancer Genome Atlas(TCGA) : an immeasurable source of knowledge", Contemp Oncol(Pozn), 19, pp.A68~A77 (2015)
39. Chakravarty D, "Somatic genomic testing in patients with metastatic or advanced cancer : ASCO provisional clinical opinion", J Clin Oncol, 40, pp.1231~1258 (2022)
40. Chakravarty D, "OncoKB : a precision oncology knowledge base", JCO Precis Oncol, 2017 (2017)
41. Lee JS, "Liquid biopsy in pancreatic ductal adenocarcinoma : current status of circulating tumor cells and circulating tumor DNA", Mol Oncol, 13, pp.1623~1650 (2019)
42. Heitzer E, "Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer", ESMO Open, 7, pp.100399~ (2022)
43. Cristiano S, "Genome-wide cell-free DNA fragmentation in patients with cancer", Nature, 570, pp.385~389 (2019)
44. Singh RR, "Next-generation sequencing in high-sensitive detection of mutations in tumors: challenges, advances, and applications", J Mol Diagn, 22, pp.994~1007 (2020)
45. Ma X, "Analysis of error profiles in deep next-generation sequencing data", Genome Biol, 20, pp.50~ (2019)
46. Abbosh C, "Early stage NSCLC – challenges to implementing ctDNA-based screening and MRD detection", Nat Rev Clin Oncol, 15, pp.577~586 (2018)
47. Heitzer E, "Current and future perspectives of liquid biopsies in genomics-driven oncology", Nat Rev Genet, 20, pp.71~88 (2019)
48. Kinde I, "Detection and quantification of rare mutations with massively parallel sequencing", Proc Natl Acad Sci U S A, 108, pp.9530~9535 (2011)
49. Wang TT, "High efficiency error suppression for accurate detection of low-frequency variants", Nucleic Acids Res, 47, pp.e87~ (2019)
50. Li Z, "The cornerstone of integrating circulating tumor DNA into cancer management", Biochim Biophys Acta Rev Cancer, 1871, pp.1~11 (2019)
51. Schmitt MW, "Detection of ultra-rare mutations by next-generation sequencing", Proc Natl Acad Sci U S A, 109, pp.14508~14513 (2012)
52. Crysup B, "Using unique molecular identifiers to improve allele calling in low-template mixtures", Forensic Sci Int Genet, 63, pp.102807~ (2023)
53. Pécuchet N, "Analysis of base-position error rate of next-generation sequencing to detect tumor mutations in circulating DNA", Clin Chem, 62, pp.1492~1503 (2016)
54. Newman AM, "Integrated digital error suppression for improved detection of circulating tumor DNA", Nat Biotechnol, 34, pp.547~555 (2016)
55. Deveson IW, "Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology", Nat Biotechnol, 39, pp.1115~1128 (2021)
56. Azad TD, "Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer", Gastroenterology, 158, pp.494~505 (2020)
57. Koessler T, "Reliability of liquid biopsy analysis : an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platforms", Lab Invest, 100, pp.1475~1484 (2020)
58. Jennings LJ, "Guidelines for validation of next-generation sequencing-based oncology panels : A joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists", J Mol Diagn, 19, pp.341~365 (2017)
59. Clarke CA, "BLOODPAC : collaborating to chart a path towards blood-based screening for early cancer detection", Clin Transl Sci, 16, pp.5~9 (2023)
60. Godsey JH, "Generic protocols for the analytical validation of next-generation sequencing-based ctDNA assays : a joint consensus recommendation of the BloodPAC’s Analytical Variables Working Group", Clin Chem, 66, pp.1156~1166 (2020)
61. "Performance evaluation guidelines for next generation sequencing in vitro diagnostic medical devices" (2021)[URL]
62. "On-site inspection evaluation checklist", Korean Institute of Genetic Testing Evaluation, ~ (2023)
63. "Laboratory accreditation program checklist, molecular diagnostic test", Korean Society for Laboratory Medicine, 2023
64. Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
65. "Sequence Variant Interpretation" (2023)[URL]
66. Horak P, "Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)", Genet Med, 24, pp.986~998 (2022)
67. Li MM, "Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists", J Mol Diagn, 19, pp.4~23 (2017)
68. Mateo J, "A framework to rank genomic alterations as targets for cancer precision medicine : the ESMO Scale for Clinical Actionability of molecular Targets(ESCAT)", Ann Oncol, 29, pp.1895~1902 (2018)
69. Wagner AH, "A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer", Nat Genet, 52, pp.448~457 (2020)
70. Bruehl FK, "Tiered somatic variant classification adoption has increased worldwide with some practice differences based on location and institutional setting", Arch Pathol Lab Med, 146, pp.822~832 (2022)
71. Larson KL, "Clinical outcomes of molecular tumor boards : a systematic review", JCO Precis Oncol, 5 (2021)
72. Jacobs MT, "Use of low-frequency driver mutations detected by cell-free circulating tumor DNA to guide targeted therapy in non-small-cell lung cancer : a multicenter case series", JCO Precis Oncol, 2, pp.1~10 (2018)
73. Helman E, "Cell-free DNA next-generation sequencing prediction of response and resistance to third-generation EGFR inhibitor", Clin Lung Cancer, 19, pp.518~530 (2018)
74. Genovese G, "Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence", N Engl J Med, 371, pp.2477~2487 (2014)
75. Acuna-Hidalgo R, "Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life", Am J Hum Genet, 101, pp.50~64 (2017)
76. Mouliere F, "Enhanced detection of circulating tumor DNA by fragment size analysis", Sci Transl Med, 10, pp.eaat4921~ (2018)
77. Stout LA, "Identification of germline cancer predisposition variants during clinical ctDNA testing", Sci Rep, 11, pp.13624~ (2021)
78. Miller DT, "ACMG SF v3. 1 list for reporting of secondary findings in clinical exome and genome sequencing : A policy statement of the American College of Medical Genetics and Genomics(ACMG)", Genet Med, 24, pp.1407~1414 (2022)
79. Li MM, "Points to consider for reporting of germline variation in patients undergoing tumor testing : a statement of the American College of Medical Genetics and Genomics(ACMG)", Genet Med, 22, pp.1142~1148 (2020)
80. Sundaresan TK, "Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses", Clin Cancer Res, 22, pp.1103~1110 (2016)
81. Abbosh C, "Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution", Nature, 545, pp.446~451 (2017)
82. Jamal-Hanjani M, "Tracking the evolution of non-small-cell lung cancer", N Engl J Med, 376, pp.2109~2121 (2017)
83. Zheng Z, "Intratumor heterogeneity : A new perspective on colorectal cancer research", Cancer Med, 9, pp.7637~7645 (2020)
84. Bourbon E, "How to obtain a high quality ctDNA in lymphoma patients : preanalytical tips and tricks", Pharmaceuticals(Basel), 14, pp.617~ (2021)
85. Bos MK, "Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA", Mol Oncol, 15, pp.57~66 (2021)
86. Georgiadis A, "Noninvasive detection of microsatellite instability and high tumor mutation burden in cancer patients treated with PD-1 blockade", Clin Cancer Res, 25, pp.7024~7034 (2019)
87. Willis J, "Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel", Clin Cancer Res, 25, pp.7035~7045 (2019)
88. Qiu P, "Measuring tumor mutational burden(TMB)in plasma from mCRPC patients using two commercial NGS assays", Sci Rep, 9, pp.114~ (2019)
89. Gandara DR, "Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab", Nat Med, 24, pp.1441~1448 (2018)
90. Marcus L, "FDA approval summary : pembrolizumab for the treatment of tumor mutational burden-high solid tumors", Clin Cancer Res, 27, pp.4685~4689 (2021)
91. Stockley T, "Evidence-based best practices for EGFR T790M testing in lung cancer in Canada", Curr Oncol, 25, pp.163~169 (2018)

관련 논문AI추천